Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited       IL0006290147

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

SummaryChartsNewsRatingsCalendarCompany 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Teva Pharmaceutical Industries : FDA Approves Teva's Migraine Drug Ajovy -- Update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/14/2018 | 08:21pm EDT

By Maria Armental

The U.S. Food and Drug Administration has approved for sale Teva Pharmaceutical Industries Ltd.'s (TEVA, TEVA.TV) migraine drug Ajovy, the latest in a new class of drugs that target a brain chemical known as CGRP.

Researchers have found that CGRP, which stands for calcitonin gene-related peptide, is involved in the brain's pain-signaling during migraines.

Ajovy should be available in about two weeks, Teva said, and its wholesale-acquisition cost--an industry term for the price drug companies charge wholesalers--will be about $575 for a 225 mg monthly dose and $1,725 for a 675 mg quarterly dose.

The most common adverse reactions in clinical trials were injection-site reactions, the company said.

Amgen Inc. and Novartis AG's Aimovig, the first of the new type of migraine drugs to hit the U.S. market, was approved in May with a list price of $6,900 a year.

Teva, the world's biggest seller of generic drugs, had been counting on the approval of Ajovy, or fremanezumab, to boost sales.

"The way we recover is Ajovy," Chief Executive Kåre Schultz said last month.

The Israeli drugmaker reported a 14% revenue decline for the first half of the year, which the company has attributed in part to continued pricing pressure in its U.S. generics business and generic competition to multiple-sclerosis drug Copaxone.

Shares, which have outperformed the market with a 21% gain this year, rose 6% to $24.25 in after-hours trading.

Write to Maria Armental at maria.armental@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
07/17Medical Distributors Stocks Fall After Opioid Data Reports
DJ
07/17Medical Distributors Stocks Fall After Opioid Data Reports
DJ
07/16TEVA PHARMACEUTICAL INDUSTRIES : Announces FDA Approval of AirDuo Digihaler Inha..
AQ
07/15JOHNSON & JOHNSON : Opioid 'kingpin' J&J fueled epidemic, Oklahoma argues at tri..
RE
07/15TEVA PHARMACEUTICAL INDUSTRIES : ADRs Down 9%; Morgan Stanley Cuts to Underweigh..
DJ
07/15TEVA PHARMACEUTICAL INDUSTRIES : Says FDA Approves AirDuo Digihaler Inhalation P..
DJ
07/15TEVA PHARMACEUTICAL INDUSTRIES : Announces FDA Approval of AirDuo® Digihaler&tra..
BU
07/15SOCIAL IMPACT AT TEVA—2018 PRO : A Conversation with Amalia Adler-Waxman
PU
07/12TEVA PHARMACEUTICAL INDUSTRIES : Completes Facilities Purchase in Pennsylvania f..
AQ
07/12TEVA PHARMACEUTICAL INDUSTRIES : Drives Progress to Address Pressing Global Heal..
AQ
More news
Chart TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Duration : Period :
Teva Pharmaceutical Industries Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani Executive Vice President-Global Operations
Michael McClellan Chief Financial Officer & Executive Vice President
Amir Elstein Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED-3.15%8 554
JOHNSON & JOHNSON2.18%350 653
PFIZER-2.08%239 061
ROCHE HOLDING LTD.11.42%234 924
ROCHE HOLDING13.37%234 924
NOVARTIS24.46%217 699